Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272–3287

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726

Article  CAS  PubMed  Google Scholar 

Niriayo YL, Asgedom SW, Demoz GT, Gidey K (2020) Treatment optimization of beta-blockers in chronic heart failure therapy. Sci Rep 10(1):15903

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barrese V, Taglialatela M (2013) New advances in beta-blocker therapy in heart failure. Front Physiol. https://doi.org/10.3389/fphys.2013.00323

Article  PubMed  PubMed Central  Google Scholar 

Lymperopoulos A, Rengo G, Koch WJ (2013) Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 113:739–753

Article  CAS  PubMed  Google Scholar 

Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol or Metoprolol European Trial Investigators (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362(9377):7–13

Article  CAS  PubMed  Google Scholar 

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658

Article  CAS  PubMed  Google Scholar 

MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007

Article  Google Scholar 

CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353:9–13

Article  Google Scholar 

Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA, Investigators SENIORS (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225

Article  CAS  PubMed  Google Scholar 

Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8(9):101

CAS  PubMed  PubMed Central  Google Scholar 

Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM (2016) Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION Trial. JACC Heart Fail 4:109–115

Article  PubMed  Google Scholar 

Ul Amin N, Sabir F, Amin T, Sarfraz Z, Sarfraz A, Robles-Velasco K, Cherrez-Ojeda I (2022) SGLT2 inhibitors in acute heart failure: a meta-analysis of randomized controlled trials. Healthcare (Basel) 10(12):2356

Article  PubMed  Google Scholar 

McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285(26):1441–1446

Article  CAS  PubMed  Google Scholar 

Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM (2016) Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail 4:109–115

Article  PubMed  Google Scholar 

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400(10367):1938–1952

Article  CAS  PubMed  Google Scholar 

Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, Thuresson M, Bozkurt B (2023) Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail 11(1):1–14

Article  CAS  PubMed  Google Scholar 

Varian KD, Ji X, Grodin JL, Verbrugge FH, Milinovich A, Kattan MW, Tang WHW (2020) Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers. ESC Heart Fail 7(5):3049–3058

Article  PubMed  PubMed Central  Google Scholar 

Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351–366

Article  PubMed  Google Scholar 

MacDonald GA, Johnston RM, Flewelling AJ (2024) A pharmacist-led heart failure stewardship initiative for guideline-directed medical therapy in hospitalized patients with reduced ejection fraction. Can Pharm J (Ott) 157(4):181–189

Article  PubMed  Google Scholar